Zobrazeno 1 - 10
of 49 190
pro vyhledávání: ''
Autor:
Lorinda Simms, Shehkar Patil, David R. Gandara, Anders Mellemgaard, Raghunadharao Digumarti, Bonne Biesma, Johan Vansteenkiste, Mauro Zukin, Joachim von Pawel, Katherine P. Sugarman, Keunchil Park, Christian Manegold, Filippo de Marinis, Tuncay Göksel, Janusz Rolski, Piotr Serwatowski, Jin S. Lee, Giorgio V. Scagliotti, Ulrich Gatzemeier, Purvish M. Parikh
Publikováno v:
Journal of Clinical Oncology. 41:2458-2466
PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS
Autor:
Ulrich Gatzemeier, Michael Boyer, Paolo Paoletti, Salih Emri, Christian Manegold, Claude Denham, Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski, Clet Niyikiza, E. Kaukel, Pierre Ruffié
Publikováno v:
Journal of Clinical Oncology. 41:2125-2133
PURPOSE Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase III trial to determine whether treatment with
Autor:
Elizabeth Bancroft, Chee Goh, Elizabeth Page, Zsofia Kote-Jarai, Elena Castro, Christos Mikropoulos, Edward J. Saunders, Nandita M. deSouza, David E. Neal, Stephen Hazell, Antonis C. Antoniou, Natalie Taylor, Pardeep Kumar, Nigel Borley, Rosalind A. Eeles, Freddie C. Hamdy, Sibel Saya, Naomi Livni, Diana Keating, Tokhir Dadaev
Publikováno v:
The Oncologist
A better assessment of prostate cancer (PrCa) risk is needed to improve screening. The PROFILE pilot study explored the feasibility of single nucleotide polymorphism profiling in men with a family history (FH) of PrCa to investigate the probability o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::530db08f3b0071b7ef326b41d3c41f1a
https://ora.ox.ac.uk/objects/uuid:5985ee3f-ba82-44cd-9894-a0e866e55da9
https://ora.ox.ac.uk/objects/uuid:5985ee3f-ba82-44cd-9894-a0e866e55da9
Autor:
Paul Mitchell, G Rivalland, Hui Yu, Fred R. Hirsch, R. Mosher, L Churilov, K Asadi, Christopher J. Rivard, S Heynemann
Publikováno v:
Clinical Lung Cancer. 23:e90-e98
Background NaPi2b is a multi-transmembrane sodium-dependent phosphate transporter expressed at normal levels in several organs, including lung. High expression levels have been reported in various tumours including breast, thyroid, ovarian and non-sm
Autor:
Cisco Espinosa, Amanda C. Meister, Kelly Drozdowicz, Howard Cabral, Sarah Singh, Eric J. Burks, Flaminio Pavesi, Ogheneyoma Akpoviroro, Virginia R. Litle, Kei Suzuki, Katrina Steiling, Sainath Asokan, Anne Buck
Publikováno v:
Clin Lung Cancer
INTRODUCTION/BACKGROUND: The USPSTF (United States Preventive Service Task Force) guidelines suggest criteria centering on smoking status and age to select patients for lung cancer screening. Despite the significant advances in screening with low-dos
Autor:
Maria Xu, Nathan Kuehne, Penelope A. Bradbury, Grainne M. O'Kane, Katrina Hueniken, Sharara Shakik, Benjamin H. Lok, M. Catherine Brown, Wei Xu, Adrian G. Sacher, Dixon Pinto, Geoffrey Liu, Ali Vedadi, Frances A. Shepherd, Natasha B. Leighl
Publikováno v:
Clinical Lung Cancer. 23:e154-e164
Recent advances in small cell lung cancer (SCLC) treatments necessitate a better understanding of real-world health utility scores (HUS) in patients treated under current standards to facilitate robust pharmaco-economic assessments.In this single ins
Autor:
Louis B. Nabors, David A. Reardon, John Simes, Lisa Roberts-Rapp, Ho-Jin Lee, Nicholas Butowski, Tobias Walbert, Andrew B. Lassman, Helen Wheeler, Priya Kumthekar, Andrew M. Scott, Peter Ansell, Tom Mikkelsen, Marta Penas-Prado, Kyriakos P. Papadopoulos, Martin J. van den Bent, Earle Bain, Zarnie Lwin, Erica Gomez, David Maag, Ryan Merrell, Hui K Gan, Hao Xiong, Kyle D. Holen
Publikováno v:
Cancer Chemotherapy & Pharmacology, 80(6), 1209-1217. Springer-Verlag
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology
Purpose Patients with recurrent glioblastoma (rGBM) have a poor prognosis. Epidermal growth factor receptor (EGFR) gene amplification is present in ~ 50% of glioblastomas (GBMs). Depatuxizumab mafodotin (depatux-m), formerly ABT-414, is an antibody
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ff65c6833473b7cdb380bda35882ca5
Autor:
Ashish Panigrahi, Constantine S. Tam, Piers Blombery, Xiangting Chen, John F. Seymour, Dennis A. Carney, Andrew H. Wei, Thomas E Lew, Mary Ann Anderson, Andrew W. Roberts, Ella R. Thompson, David C. S. Huang, Tamia Nguyen, David Westerman, Michael A. Dengler, Victor S Lin, Sasanka M. Handunnetti, Jerry M. Adams
Publikováno v:
Blood. 139:1198-1207
The BCL2 inhibitor venetoclax has established therapeutic roles in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). As BCL2 is an important determinant of survival of both myeloid progenitor and B cells, we investigated whether cl
Autor:
Kiki C. Andree, Menno Tamminga, Harry J.M. Groen, T. Jeroen N. Hiltermann, Ed Schuuring, Leon W.M.M. Terstappen, Anouk Mentink, Hilda van den Bos, Peter M. Lansdorp, Wim Timens, Diana C.J. Spierings
Publikováno v:
British journal of cancer, 126, 409-418. Nature Publishing Group
Br J Cancer
British Journal of Cancer, 126. Nature Publishing Group
Br J Cancer
British Journal of Cancer, 126. Nature Publishing Group
BACKGROUND: Circulating tumour cells (CTCs) can be used to monitor cancer longitudinally, but their use in non-small cell lung cancer (NSCLC) is limited due to low numbers in the peripheral blood. Through diagnostic leukapheresis (DLA) CTCs can be ob
Autor:
Hong Luo, Yi Hu, Patricia Keegan, Hongqian Guo, Ji-Yan Liu, Haige Chen, Sheng Yao, Weifeng Wang, Jun Guo, Fangjian Zhou, Xudong Yao, Benkang Shi, Zhigang Ji, Hui Feng, Xinan Sheng, Zhisong He, Bin Hu, Ziling Liu, Jin Wu, Xin Yao, Jinhai Fan, Yiran Huang
Publikováno v:
Clinical Cancer Research. 28:489-497
Purpose: Immunotherapy offers a second-line option for patients with metastatic urothelial carcinoma (mUC) who failed standard therapy, but the biomarkers for predicting response remain to be explored. This study aims to evaluate the safety, efficacy